BrainStorm Cell Therapeutics has an upcoming top-line data readout for the NurOwn® Phase 3 trial in ALS, expected by the end of November.
The implied volatility (IV) is extremely high right now for December expiration options (image below). $5 strike could potentially get $2 which is equivalent to more than 30% return in two months (about 15%/month) and brings down the breakeven point to $3.
While BCLI stock price is declining right now, the baseline price was around $4 before a large jump that occurred in February 2020 (image below).
Assuming the stock price does not decrease beyond $4 in the next couple of months, this could be a great opportunity for premium sellers.
Please note this is presented for informational purposes only. Please carry out your own diligence carefully.
Below is more information from seekingalpha.com
BrainStorm Cell Therapeutics Q3 results and the company prepares to transition to a commercial organization.
Net loss was $4.49M or EPS loss of $0.14, vs. net loss of $5.63M or EPS loss of $0.25 last year.
Cash and cash equivalents, and short-term bank deposits amounted to approximately $28.8M at September 30, 2020 compared to $16.2M at June 30, 2020.
The company remains on track to complete dosing in its Phase 2 clinical trial in progressive multiple sclerosis (or PMS) by the end of 2020.
CEO Chaim Lebovits comments : “The most important near-term event for BrainStorm will be the upcoming top-line data readout for the NurOwn® Phase 3 trial in ALS, expected by the end of November. A successful outcome will set us on the path to filing a Biologic License Application (or BLA) for what we believe will be a valuable new treatment for ALS.”